Search results for "ion therapy"

showing 10 items of 1072 documents

2020

Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies such as chemotherapy, radiation, or vaccines, which can stimulate the immune system and recruit antitumor T cells into the tumor bed, may be a relevant strategy to increase the proportion of responding patients. Such an approach still raises the following questions: What are the immunological features modulated by immunogenic therapies that can be critical to ensure not only immediate but also l…

0301 basic medicineChemotherapyTumor microenvironmentbusiness.industrymedicine.medical_treatmentImmune checkpoint inhibitorsCancerGeneral Medicinemedicine.disease3. Good healthRadiation therapy03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemCancer immunotherapy030220 oncology & carcinogenesisCancer researchmedicinePermissivebusinessCells
researchProduct

A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin

2019

International audience; The link between colorectal cancer (CRC), diabetes mellitus (DM) and inflammation is well established, and polytherapy, including rapamycin, has been adopted. This study is a novel approach that aimed at assessing the effect of a combination therapy of metformin and rapamycin on the control or prevention of CRC in diabetic animals, in presence or absence of probiotics. Fifty NOD/SCIDs male mice developed xenograft by inoculating HCT116 cells. They were equally divided into diabetics (induced by Streptozotocin) and non-diabetics. Metformin was given in drinking water, whereas rapamycin was administered via intra-peritoneal injections. Probiotics were added to the doub…

0301 basic medicineCombination therapyColorectal cancerinflammatory cytokinesSettore BIO/11 - Biologia MolecolareInflammationcolorectal cancer[SDV.CAN]Life Sciences [q-bio]/CancerPharmacologyProinflammatory cytokine03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerDiabetes mellituscolorectal cancer biabetes therapeutic approachMedicinePI3K/AKT/mTOR pathwaybusiness.industryCorrectionmedicine.disease3. Good healthMetforminSettore MED/18 - Chirurgia Generale030104 developmental biologyOncologyprobiotics030220 oncology & carcinogenesisdiabetes mellitusmTORTumor necrosis factor alphamedicine.symptombusinessmedicine.drugResearch Paper
researchProduct

Introduction: Novel hybrid combinations containing synthetic or antibiotic drugs with plant-derived phenolic or terpenoid compounds

2017

Abstract Background There is a paradigm shift in chemotherapy from mono-drug therapy towards multidrug combination regimens. Natural products from medicinal plants may play an important role for the design of novel combination therapy protocols. Hypothesis We introduce the novel term “hybrid combination” for the therapeutic combination of chemically defined plant-derived constituents (e.g. phenolic or terpenoid compounds with synthetic or antibiotic drugs to increase pharmacological activity and simultaneously toxic side effects. Study design Several literature databases were screened on the combination of phenolic/terpenoid compounds with synthetic/antibiotic drugs. Results Phenolic compou…

0301 basic medicineCombination therapymedicine.drug_classAntibioticsHerb-Drug InteractionsPharmaceutical ScienceDrug resistancePharmacologyAntioxidants03 medical and health sciencesPhenolsNetwork pharmacologyDrug DiscoverymedicineHumansOrganic chemistryMedicinal plantsAntibiotic DrugsPharmacologyBiological ProductsPlants MedicinalPlant ExtractsTerpenesChemistryBiological activityTerpenoidAnti-Bacterial Agents030104 developmental biologyComplementary and alternative medicineMolecular MedicineDrug Therapy CombinationPhytomedicine
researchProduct

Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib.

2017

Abstract Background The shift from cytotoxic to targeted chemotherapy led to improved treatment outcomes in oncology. Nevertheless, many cancer patients cannot be cured from their disease because of the development of drug resistance and side effects. Purpose There is an ongoing quest for novel compounds, which raised not only the interest in natural products but also in novel combination therapy regimens. Study design In this review, we report on the inhibition epidermal growth factor receptor (EGFR) by targeted small molecules and their combination with natural products from medicinal plants. Results The combination of erlotinib with artesunate leads to synergistic inhibition of cell grow…

0301 basic medicineCombination therapymedicine.medical_treatmentPharmaceutical ScienceArtesunateDrug resistancePharmacology03 medical and health scienceschemistry.chemical_compoundErlotinib Hydrochloride0302 clinical medicineIn vivoDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansEpidermal growth factor receptorMolecular Targeted TherapyProtein Kinase InhibitorsPharmacologyChemotherapybiologybusiness.industryCancermedicine.diseaseArtemisininsErbB Receptors030104 developmental biologyComplementary and alternative medicinechemistryArtesunate030220 oncology & carcinogenesisbiology.proteinMolecular MedicineErlotinibbusinessmedicine.drugPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Cancer combination therapies with artemisinin-type drugs

2017

Artemisia annua L. is a Chinese medicinal plant, which is used throughout Asia and Africa as tea or press juice to treat malaria. The bioactivity of its chemical constituent, artemisinin is, however, much broader. We and others found that artemisinin and its derivatives also exert profound activity against tumor cells in vitro and in vivo. Should artemisinin-type drugs be applied routinely in clinical oncology in the future, then it should probably be as part of combination therapy regimens rather than as monotherapy. In the present review, I give a comprehensive overview on synergistic and additive effects of artemisinin-type drugs in combination with different types of cytotoxic agents an…

0301 basic medicineDrugCombination therapymedicine.medical_treatmentmedia_common.quotation_subjectArtemisia annuaDrug resistancePharmacologyBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoCell Line TumorNeoplasmsAntineoplastic Combined Chemotherapy Protocolsparasitic diseasesmedicineAnimalsHumansDrug InteractionsArtemisininmedia_commonPharmacologyBiological ProductsChemotherapyNatural productbiologybusiness.industryDrug SynergismDrugs Investigationalbiology.organism_classificationAntineoplastic Agents PhytogenicCombined Modality TherapyArtemisininsDrug Resistance Multiple030104 developmental biologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisChemical and Drug Induced Liver InjurybusinessSesquiterpenesmedicine.drugBiochemical Pharmacology
researchProduct

Shikonin derivatives for cancer prevention and therapy.

2019

Abstract Phytochemicals gained considerable interest during the past years as source to develop new treatment options for chemoprevention and cancer therapy. Motivated by the fact that a majority of established anticancer drugs are derived in one way or another from natural resources, we focused on shikonin, a naphthoquinone with high potentials to be further developed as preventive or therapeutic drug to fight cancer. Shikonin is the major chemical component of Lithospermum erythrorhizon (Purple Cromwell) roots. Traditionally, the root extract has been applied to cure dermatitis, burns, and wounds. Over the past three decades, the anti-inflammatory and anticancer effects of root extracts, …

0301 basic medicineDrugModels MolecularCancer Researchmedicine.medical_treatmentmedia_common.quotation_subject03 medical and health sciencesStructure-Activity Relationship0302 clinical medicineNeoplasmsMedicineAnimalsHumansmedia_commonCancer preventionTraditional medicinebiologybusiness.industryCancerImmunotherapyLithospermum erythrorhizonbiology.organism_classificationmedicine.diseaseAntineoplastic Agents PhytogenicClinical trialRadiation therapy030104 developmental biologyOncologyPhytochemical030220 oncology & carcinogenesisbusinessDrugs Chinese HerbalNaphthoquinonesCancer letters
researchProduct

2020

Skeletal muscle injuries in competitive sports cause lengthy absences of athletes from tournaments. This is of tremendous competitive and economic relevance for both the athletes and their respective clubs. Therapy for structural muscle lesions aims to promote regeneration and fast-track return-to-play. A common clinical treatment strategy for muscle injuries is the intramuscular injection of calf blood compound and the homeopathic drug, Tr14. Although the combination of these two agents was reported to reduce recovery time, the regulatory mechanism whereby this occurs remains unknown. In this in vivo study, we selected a rat model of mechanical muscle injury to investigate the effect of th…

0301 basic medicineDrugmedicine.medical_specialtyCombination therapySports medicinemedia_common.quotation_subjectPharmacologyCatalysisInorganic Chemistry03 medical and health sciences0302 clinical medicineIn vivoGene expressionMedicinePhysical and Theoretical ChemistryMolecular BiologySpectroscopymedia_commonbusiness.industryRegeneration (biology)Organic ChemistrySkeletal muscle030229 sport sciencesGeneral MedicineComputer Science Applications030104 developmental biologymedicine.anatomical_structurebusinessIntramuscular injectionInternational Journal of Molecular Sciences
researchProduct

Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia

2017

Several risk factors such as abnormality of lipid metabolism (e.g. high levels of low-density lipoprotein cholesterol (LDL-C), elevated triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C)) play a central role in the aetiology of cardiovascular disease (CVD). Nutraceutical combination together with a cholesterol- lowering action, when associated with suitable lifestyle, should furnish an alternative to pharmacotherapy in patients reporting statin-intolerance and in subjects at low cardiovascular risk. The present review is focused on nutraceuticals and their synergetic combinations demonstrating a beneficial effect in the management of dyslipidaemia. Several nutraceu…

0301 basic medicineDyslipidaemiaCombination therapyLow density lipoprotein cholesterol030204 cardiovascular system & hematologyReductaseBiologyPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalBerberineDrug DiscoverymedicineRed yeast riceHumansEndothelial dysfunctionEndothelial dysfunctionDyslipidemiasCarotidDietary SupplementPharmacologyCholesterolLipid metabolismLipidCardiovascular riskmedicine.diseaseLipidsIntima media thickne030104 developmental biologyDyslipidemiachemistryDietary SupplementsDrug Therapy Combinationlipids (amino acids peptides and proteins)NutraceuticalHumanCurrent Pharmaceutical Design
researchProduct

Monitoring of rheologic variables during postoperative high-dose brachytherapy for uterine cancer.

2004

Oxygenation of tumor tissue has recently been assed an important prerequisite for the effectiveness of radiotherapy in cervical cancer. Hyperviscosity is a common phenomenon in malignancy and a cause of reduced oxygen transport capacity that would favour tissue hypoxia. Hemorheological variables were serially tested preoperatively, during four cycles of fractionated adjuvant IR192 HDR after loading radiation (HDR-AL) of the vaginal vault (weekly intervals), and 6 months postoperatively in patients with cervical (n=12) and endometrial cancer (n=26). Women who were scheduled for benign tumor surgery served as controls (n=29). Preoperatively, in cervical and endometrial cancer patients, mean …

0301 basic medicineErythrocyte Aggregationmedicine.medical_specialtymedicine.medical_treatmentBrachytherapyBrachytherapyUrologyUterine Cervical Neoplasms030204 cardiovascular system & hematologyHysterectomy03 medical and health sciencesLeukocyte Count0302 clinical medicineUterine cancermedicineHumansAgedCervical cancerbusiness.industryPlatelet CountEndometrial cancerOxygen transportFibrinogenHematologyGeneral MedicineMiddle Agedmedicine.diseaseBlood ViscosityCombined Modality TherapyCell HypoxiaSurgeryEndometrial NeoplasmsRadiation therapy030104 developmental biologyHemorheologyVaginal vaultFemaleRadiotherapy AdjuvantbusinessBiomarkersClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

2020

Abstract HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of m…

0301 basic medicineFulvestrantCombination therapybusiness.industryEstrogen receptormedicine.diseaseMetastatic breast cancer03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncologyTrastuzumab030220 oncology & carcinogenesisNeratinibmedicineCancer researchSignal transductionskin and connective tissue diseasesbusinessmedicine.drugCancer Discovery
researchProduct